A 10-year Actos study showed that people who took the medication for more than one year had an increased risk of getting cancer — about 40 percent. Many of the Actos users who did contract bladder cancer have filed a suit against Takeda pharmaceuticals Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. It is a disease in which cells grow abnormally and have the potential to spread to other parts of the body. The diabetes medication Actos has been the focus of bladder cancer concerns in recent years.Age and gender – There is a correlation with increasing age for the risk of bladder cancer. 9 out of 10 bladder cancer patients are over 55. Actos may be linked to bladder cancer, you may have legal claim for your condition.Over 10,000 people are diagnosed with bladder cancer in the UK each year and over 50,000 annually in the US. According to the FDA, the use of Actos can lead to a 40% increased risk of Bladder Cancer. This information is based on a 10-year study of more than 200,000 patients with type 2 diabetes. Actos is manufactured by Takeda Pharmaceuticals. Recently, the FDA issued a warning saying people who have been taking the drug for a year or longer have an increased risk of developing bladder cancer. Interim results from a 10-year American study found According to the FDA, in two additional three-year studies, researchers noted a higher incidence of bladder cancer in patients who took Actos versus those who took other drugs. As a result of these studies, the FDA required that Takeda undertake a 10-year study of the drug’s link to bladder cancer. (MedPage Today) -- Topline results from a 10-year analysis of diabetic patients treated with pioglitazone ( Actos) indicated no increased risk of bladder cancer, even with long-term use, the drug's manufacturer said. The first communication, issued in September 2010, indicated the agency was looking into the possible increased risk after a tabletki jak viagra bez recepty then-ongoing 10-year study found an association between Actos and bladder cancer. On June 15, 2011, the FDA issued an “urgent health warning” after a review of studies showing up to a 40% increased risk of developing Bladder Cancer after a patient had been on Actos for more than a year. An ongoing 10-year study suggests that long-term Actos use may increase bladder cancer risk.Early Data Linking Actos to Bladder Cancer Spurs FDA Safety Review. Safety Announcement. [09-17-2010] The U.S. Food and Drug Administration (FDA) is reviewing data from an ongoing, ten-year epidemiological study designed to evaluate whether Actos (pioglitazone), is associated with an increased risk of bladder cancer. A U-Turn and amitriptyline and xanax together “All Clear” on Actos and Bladder Cancer: On July 31, 2015 Takeda Pharmaceutical Company, announced the results of a 10-year post-marketing study: “Findings demonstrate that there is no association between the use of pioglitazone and the risk of bladder cancer. The FDA also carried out research that backed up this information and claimed that when Actos delivered a 10 year study, nothing about the possible side effects of bladder cancer was mentioned. Actos Bladder Cancer Heart Injury Lawsuit. Actos is a brand name for the drug pioglitazone.Permalink. Guest. on November 30, 2011 at 10:44 pm. I started taking Actos in 2005 for about 2 years. On Sept 30, 2011, the FDA reviewed the findings of a 10-year study done by manufacturer Takeda Pharmaceuticals. This study determined that Actos® (pioglitazone) carries a greater than average risk of developing bladder cancer. Possible signs of Actos bladder cancer may include blood in the urine, frequent urination, and the need to urinate without results. viagra pills The Food and Drug Administration (FDA) recently required the manufacturer to warn of the increased risk of bladder cancer if taken for a year or longer. The FDA added the increased bladder cancer risk to the Warnings and Precautions section on the label for Actos. This was based on the five-year analysis of data from the currently ongoing 10-year study. Experts fear as many as 10,000 patients may eventually be affected.At that time, the European Medicines Agency published a French study which discovered those taking Actos for more than a year had as much as a 40% increased occurrence of bladder cancer. Actos Bladder Cancer. Commonly monitored possible A ctos side effects are swelling (edema), congestive heart failure (CHF), swelling in the eye, inflammation of the liver (hepatitis), anemia, and fracturesThis was based on the five-year analysis of data from the currently ongoing 10-year study.